Inside lab’s experience with assays for Alzheimer’s

2023 Issues, ARTICLES, Immunoassay, October 2023

October 2023—Orders for cerebrospinal fluid testing for Alzheimer’s disease have grown at Mayo Clinic since spring 2020, when testing was first offered. When aducanumab was approved in May 2021, test orders jumped.

Alzheimer’s biomarkers: CSF reports, plasma prospects

2023 Issues, ARTICLES, Immunoassay, May 2023

May 2023—For fluid biomarkers in the diagnosis of Alzheimer’s disease, the pace of research and related industry and regulatory developments in the past year has been brisk.